Tislelizumab,Sorafenib
BeiGene,bayer,novartis
['tislelizumab', 'beigene']
beigene announces data presentations at esmo 2022 including late-breaking oral presentation for tislelizumab in first-line unresectable hepatocellular cancer #pharmanews #clinicalresearchnews #biotechnews #lifesciencesnews #medicalnews #healthcarenews #pha 
News from across the pharmaceutical and biotech industry from PharmiWeb https://t.co/ea1b58MZYg